[Clinical aspects of control in therapy with platelet inhibitors].
46 patients with ischaemic heart disease were treated with Micristin (20-40 mg/kg) or a combination of Micristin and Propranolol (80-120 mg/die). The values of bleeding time, the platelet factor 4 in lysate of thrombocytes or in plasma of patients as well as the soluble fibrin monomer complexes were investigated. They showed no obvious correlation to the clinical findings.
D000244:Adenosine Diphosphate; D001241:Aspirin / Q000627:therapeutic use*; D001780:Blood Coagulation Tests; D001792:Blood Platelets / Q000187:drug effects*; D003327:Coronary Disease / Q000188:drug therapy*; D005337:Fibrin / Q000032:analysis; D006801:Humans; D010973:Platelet Adhesiveness / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D010978:Platelet Factor 4 / Q000032:analysis; D011433:Propranolol / Q000627:therapeutic use
D010978:Platelet Factor 4; D000244:Adenosine Diphosphate; D005337:Fibrin; D011433:Propranolol; D001241:Aspirin
Klinische Aspekte der Kontrolle bei der Therapie mit Thrombozytenhemmstoffen.